In 2018, non-surgical hyaluronic acid (HA) treatments surged in popularity by an impressive 54%. Approximately $544 million was spent on these procedures. Among these, injectable dermal fillers emerged as the second most popular non-invasive cosmetic treatment. This ranking highlights their significant role in the beauty industry.
CHA Meditech Co., Ltd., a leading bio-aesthetics company based in South Korea, is at the forefront of this growing demand. Specializing in biomaterials, cosmetics, and medical devices, CHA Meditech has built a reputation for innovation and quality in facial aesthetics and minimally invasive enhancements. The company is best known for its Hyafilia brand, offering a versatile range of dermal fillers.
This article will delve into the story of CHA Meditech Co., Ltd., the Hyafilia manufacturer, exploring its history, expertise in medical aesthetics, and innovative medical devices.
Key Takeaways
- CHA Meditech Co., Ltd. has been active in bio-aesthetics for over a decade. They specialize in developing and manufacturing various raw biomaterials and products.
- Established in August 2013, CHA Meditech Co., Ltd. originated from the medical device development division of CHA Biotech, a subsidiary of the CHA Bio Group.
- Beyond its biomaterials and cosmetics, CHA Meditech’s medical devices have become distinctive and powerful solutions for facial aesthetics, specifically the Hyafilia fillers.
- Hyafilia fillers feature V-Phasic Technology, integrating bi-phasic and mono-phasic fillers for elasticity, cohesiveness, and durability.
About: Medica Depot is your trusted all-in-one supplier, offering a range of high-quality medical injectables and supplies. Buy Hyafilia at Medica Depot today! Whether for health professionals, plastic surgeons, dermatologists, licensed estheticians, or other specialists, we can offer genuine, brand-name products you may need. With Medica Depot, we prioritize serving you better to improve the patient’s quality of life.
Introduction to CHA Meditech Co., Ltd.
In the highly competitive South Korean bio-aesthetics market, CHA Meditech Co., Ltd. has emerged as a leader with over a decade of experience. The company specializes in developing and manufacturing advanced biomaterials and products, catering to the growing demand for high-quality aesthetic solutions. With a strong focus on global business expansion, CHA Meditech exports its products worldwide through its established brands and OEM partnerships.
Although CHA Meditech does not have a formal mission or vision statement, it is driven by a dedication to improving human lifestyles through cutting-edge bio-aesthetic innovations. The company aims to lead the bio-aesthetic market by offering advanced technologies and top-tier products that enhance beauty and well-being.
History of CHA Meditech Co., Ltd.
Founded in August 2013, CHA Meditech Co., Ltd. originated from the medical device development division of CHA Biotech, a subsidiary of the renowned CHA Bio Group. Since its inception, the company has focused on developing innovative biomaterials, including growth factors, peptides, and natural extracts, for medical devices, pharmaceuticals, and cosmetics.
CHA Meditech has achieved several significant milestones in its journey to becoming a leader in the bio-aesthetics industry:
- 2013: Established as a standalone entity specializing in biomaterial innovation.
- GMP Certification: Received approval from Korea’s Ministry of Food and Drug Safety (MFDS), ensuring adherence to high manufacturing standards.
- ISO Certification: Achieved European ISO certification, validating its commitment to quality and safety.
- Global Expansion: Broadened its footprint by exporting products internationally through Hyafilia fillers and OEM manufacturing partnerships.
While the company’s Hyafilia SMV fillers are not yet FDA-approved, they have received CE certifications and meet European safety and quality standards. Backed by exceptional talent and proprietary technologies, CHA Meditech continues to innovate and expand, solidifying its reputation as a pioneer in the bio-aesthetics field.
Expertise in Medical Aesthetics
CHA Meditech Co., Ltd. has established itself as a leader in dermatology and medical aesthetics, driven by its cutting-edge research and technological expertise. The company’s progress is rooted in its globally recognized capabilities in bio-engineering and its skilled team, which was developed through the CHA Biomedical Placental Research Center.
Beyond biomaterials and cosmetics, CHA Meditech has made significant strides in medical devices. Over the years, they have introduced innovative solutions for facial rejuvenation and body contouring. Its dedication to research and development has resulted in the creation of a diverse range of fillers under the Hyafilia brand:
- SMV and SMV Plus (with lidocaine): Designed to temporarily address facial wrinkles and aging signs, providing smoother and more youthful skin.
- Impact: Developed for body contouring, including the enhancement of male intimate areas, offering a unique solution in the aesthetics market.
- Dorothy Dewy: Targets facial wrinkles, restores lost volume, and rejuvenates the skin for a refreshed, natural appearance.
CHA Meditech’s research extends to growth factors, peptides, and natural extracts, ensuring the highest quality standards and continuous innovation. As the Hyafilia manufacturer, the company is committed to advancing medical aesthetics through groundbreaking technologies and tailored solutions for patient needs.
Hyafilia Fillers
As a leading bio-aesthetics company, CHA Meditech employs unique technologies to create innovative formulations for its medical devices. When comparing Hyafilia vs Juvederm, Hyafilia leverages its proprietary V-Phasic Technology, combining the benefits of bi-phasic and mono-phasic fillers. This hybrid structure utilizes high-purity, cross-linked hyaluronic acid (HA) to deliver safe, effective, and natural-looking results.
Hyafilia’s advanced formulation ensures superior elasticity, cohesiveness, and durability. This makes it ideal for achieving smooth facial contours, reducing aging signs, and providing long-lasting outcomes. Additionally, three Hyafilia injectables have earned CE certifications, underscoring their proven safety and efficacy as minimally invasive solutions.
The manufacturer prioritizes safety and maintains stringent quality standards throughout the production process. A clinical study found that Hyafilia offers longer-lasting effects than Restylane and Juvederm, with minimal side effects. Its smooth application minimizes patient discomfort, enhancing satisfaction and trust in the product.
Conclusion
CHA Meditech Co., Ltd. has firmly established itself as a pioneer in the bio-aesthetics industry, driven by its innovative Hyafilia dermal fillers. With a steadfast commitment to quality, safety, and technological excellence, the company continues to develop effective solutions that meet the growing global demand for minimally invasive aesthetic treatments.
As CHA Meditech expands its global footprint, the recognition of its products reinforces its status as a trusted leader in medical aesthetics. Through ongoing innovation and a dedication to excellence, the company is poised for continued success and growth in this competitive field.
FAQs
1. What is CHA Meditech Co., Ltd. known for?
CHA Meditech Co., Ltd. is recognized as a leading bio-aesthetics company in South Korea. It specializes in developing and manufacturing dermal fillers, biomaterials, and medical devices, particularly under its Hyafilia brand.
2. What technology does Hyafilia use in its fillers?
Hyafilia utilizes V-Phasic Technology, which combines bi-phasic and mono-phasic fillers. This innovative approach incorporates high-purity, cross-linked hyaluronic acid, resulting in formulations that offer superior elasticity, cohesiveness, and long-lasting results.
3. Have Hyafilia fillers received any certifications?
Several Hyafilia injectable products have received CE certifications. This supports their safety and effectiveness as minimally invasive aesthetic solutions, although they have not yet received FDA approval.
References
- The Aesthetic Society. (n.d.). The Aesthetic Society releases annual statistics revealing significant increases in face, breast, and body in 2021. https://www.theaestheticsociety.org/media/press-releases/aesthetic-society-releases-annual-statistics-revealing-significant-increases
- Jang, J.-C., Shin, S.-H., Han, S.-K., Kim, W.-K., 장준철, 신수혜, 한승규, & 김우경. (2016). The Efficacy of New Hyaluronic Acid Filler (HyaFilia). Archives of Plastic Surgery, 38(1), 1–6. https://koreascience.kr/article/JAKO201119535548468.page
